🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TVs6b9
@ASCO

#SocialListening #LucidQuest

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TVk8mN
@ASCO

#SocialListening #LucidQuest

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TVZrrx
@ASCO

#SocialListening #LucidQuest

Family history of #ColorectalCancer increased the risk of #CRC similarly between patients with #IBD and the general population. Those with multiple relatives with CRC showed the highest increase in CRC risk. #IBDSky #GISky #GIOnc

www.docwirenews.com/post/family-...

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TVRwF2
@ASCO

#SocialListening #LucidQuest

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TVJN5b
@ASCO

#SocialListening #LucidQuest